| First Author | Arndt S | Year | 2019 |
| Journal | J Invest Dermatol | Volume | 139 |
| Issue | 9 | Pages | 1914-1924.e6 |
| PubMed ID | 30878675 | Mgi Jnum | J:283928 |
| Mgi Id | MGI:6387938 | Doi | 10.1016/j.jid.2019.02.020 |
| Citation | Arndt S, et al. (2019) Bone Morphogenetic Protein-6 Inhibits Fibrogenesis in Scleroderma Offering Treatment Options for Fibrotic Skin Disease. J Invest Dermatol 139(9):1914-1924.e6 |
| abstractText | BMP6 is known to be crucial for regulating embryonic skin development. This study assessed the role of BMP6 in dermal fibrosis. We detected that BMP6 is significantly increased in skin-derived fibroblasts of patients with localized scleroderma. Moreover, it was shown that BMP6 significantly impacts proliferation, migration, cytoskeletal organization, and collagen expression, as well as activity of the major pro-fibrogenic transcription factor AP-1 in dermal fibroblasts. The importance of BMP6 in dermal fibrosis was further confirmed in an in vivo model of dermal fibrosis in which BMP6-deficient mice showed significantly enhanced fibrosis compared with wild-type mice. Conversely, application of recombinant BMP6 significantly ameliorated dermal fibrosis in this preclinical bleomycin-induced sclerosis model, and herewith provided proof of concept for the successful treatment of this fibrotic skin disease. |
